Degarelix as a new antiangiogenic agent for metastatic colon cancer?
Fiche publication
Date publication
février 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Dr LADOIRE Sylvain
Tous les auteurs :
Ghiringhelli F, Isambert N, Ladoire S
Lien Pubmed
Résumé
Recently, follicle stimulating hormone receptor was found to be selectively expressed by endothelial cells on tumor-associated blood vessels in a wide range of human cancers. In this context, we hypothesized that degarelix, a new gonadotropin-releasing hormone receptor antagonist developed for patients with prostate cancer, may have antiangiogenic effects via its capacity to block follicle stimulating hormone (FSH) production. We report the case of a patient with metastatic colon cancer exhibiting tumor progression after failure of all conventional chemotherapeutic regimens. The addition of degarelix to the last chemotherapeutic regimen was proposed as compassionate treatment. Degarelix induced a rapid decrease in FSH level. This treatment induced radiological stabilization and carcinoembryonic antigen stabilization during 1 year. Contrast-enhanced ultrasonography demonstrated reduction of tumor vasculature. This case represents the first report of an antitumoral effect of degarelix in metastatic colon cancer and suggests an antiangiogenic property of this drug.
Référence
World J Gastroenterol. 2013 Feb 7;19(5):769-72